BACKGROUND: A single family has been described in which obesity results from a mutation in the leptin-receptor gene (LEPR), but the prevalence of such mutations in severe, early-onset obesity has not been systematically examined. METHODS: We sequenced LEPR in 300 subjects with hyperphagia and severe early-onset obesity, including 90 probands from consanguineous families, and investigated the extent to which mutations cosegregated with obesity and affected receptor function. We evaluated metabolic, endocrine, and immune function in probands and affected relatives. RESULTS: Of the 300 subjects, 8 (3%) had nonsense or missense LEPR mutations--7 were homozygotes, and 1 was a compound heterozygote. All missense mutations resulted in impaired receptor signaling. Affected subjects were characterized by hyperphagia, severe obesity, alterations in immune function, and delayed puberty due to hypogonadotropic hypogonadism. Serum leptin levels were within the range predicted by the elevated fat mass in these subjects. Their clinical features were less severe than those of subjects with congenital leptin deficiency. CONCLUSIONS: The prevalence of pathogenic LEPR mutations in a cohort of subjects with severe, early-onset obesity was 3%. Circulating levels of leptin were not disproportionately elevated, suggesting that serum leptin cannot be used as a marker for leptin-receptor deficiency. Congenital leptin-receptor deficiency should be considered in the differential diagnosis in any child with hyperphagia and severe obesity in the absence of developmental delay or dysmorphism. Copyright 2007 Massachusetts Medical Society.
BACKGROUND: A single family has been described in which obesity results from a mutation in the leptin-receptor gene (LEPR), but the prevalence of such mutations in severe, early-onset obesity has not been systematically examined. METHODS: We sequenced LEPR in 300 subjects with hyperphagia and severe early-onset obesity, including 90 probands from consanguineous families, and investigated the extent to which mutations cosegregated with obesity and affected receptor function. We evaluated metabolic, endocrine, and immune function in probands and affected relatives. RESULTS: Of the 300 subjects, 8 (3%) had nonsense or missense LEPR mutations--7 were homozygotes, and 1 was a compound heterozygote. All missense mutations resulted in impaired receptor signaling. Affected subjects were characterized by hyperphagia, severe obesity, alterations in immune function, and delayed puberty due to hypogonadotropic hypogonadism. Serum leptin levels were within the range predicted by the elevated fat mass in these subjects. Their clinical features were less severe than those of subjects with congenital leptin deficiency. CONCLUSIONS: The prevalence of pathogenic LEPR mutations in a cohort of subjects with severe, early-onset obesity was 3%. Circulating levels of leptin were not disproportionately elevated, suggesting that serum leptin cannot be used as a marker for leptin-receptor deficiency. Congenital leptin-receptor deficiency should be considered in the differential diagnosis in any child with hyperphagia and severe obesity in the absence of developmental delay or dysmorphism. Copyright 2007 Massachusetts Medical Society.
Authors: Fahrettin Kelestimur; Vera Popovic; Alfonso Leal; P Sytze Van Dam; Elena Torres; Luisa F Perez Mendez; Yona Greenman; Hans P F Koppeschaar; Carlos Dieguez; Felipe F Casanueva Journal: Clin Endocrinol (Oxf) Date: 2006-06 Impact factor: 3.478
Authors: I Sadaf Farooqi; Julia M Keogh; Giles S H Yeo; Emma J Lank; Tim Cheetham; Stephen O'Rahilly Journal: N Engl J Med Date: 2003-03-20 Impact factor: 91.245
Authors: Julio Licinio; Sinan Caglayan; Metin Ozata; Bulent O Yildiz; Patricia B de Miranda; Fiona O'Kirwan; Robert Whitby; Liyin Liang; Pinchas Cohen; Shalender Bhasin; Ronald M Krauss; Johannes D Veldhuis; Anthony J Wagner; Alex M DePaoli; Samuel M McCann; Ma-Li Wong Journal: Proc Natl Acad Sci U S A Date: 2004-03-09 Impact factor: 11.205
Authors: William T Gibson; I Sadaf Farooqi; Mary Moreau; Alex M DePaoli; Elizabeth Lawrence; Stephen O'Rahilly; Rebecca A Trussell Journal: J Clin Endocrinol Metab Date: 2004-10 Impact factor: 5.958
Authors: N Lahlou; K Clement; J C Carel; C Vaisse; C Lotton; Y Le Bihan; A Basdevant; Y Lebouc; P Froguel; M Roger; B Guy-Grand Journal: Diabetes Date: 2000-08 Impact factor: 9.461
Authors: M Heo; R L Leibel; K R Fontaine; B B Boyer; W K Chung; M Koulu; M K Karvonen; U Pesonen; A Rissanen; M Laakso; M I J Uusitupa; Y Chagnon; C Bouchard; P A Donohoue; T L Burns; A R Shuldiner; K Silver; R E Andersen; O Pedersen; S Echwald; T I A Sørensen; P Behn; M A Permutt; K B Jacobs; R C Elston; D J Hoffman; E Gropp; D B Allison Journal: Int J Obes Relat Metab Disord Date: 2002-05
Authors: I Sadaf Farooqi; Giuseppe Matarese; Graham M Lord; Julia M Keogh; Elizabeth Lawrence; Chizo Agwu; Veronica Sanna; Susan A Jebb; Francesco Perna; Silvia Fontana; Robert I Lechler; Alex M DePaoli; Stephen O'Rahilly Journal: J Clin Invest Date: 2002-10 Impact factor: 14.808
Authors: Cecilia Martin; Ravikumar Balasubramanian; Andrew A Dwyer; Margaret G Au; Yisrael Sidis; Ursula B Kaiser; Stephanie B Seminara; Nelly Pitteloud; Qun-Yong Zhou; William F Crowley Journal: Endocr Rev Date: 2010-10-29 Impact factor: 19.871